What is Mod GRF 1-29?
Mod GRF 1-29 (modified GRF 1-29) is an alternative research-supply name for CJC-1295 No DAC — the short-acting GHRH analogue consisting of the first 29 amino acids of human GHRH with four protease-resistance substitutions, but without the Drug Affinity Complex (DAC) albumin-binding moiety carried by the long-acting CJC-1295 DAC variant.
What the research literature says
The naming history: the compound corresponds to GHRH(1-29) with four amino-acid substitutions at positions 2, 8, 15, and 27 (D-Ala, Gln, Ala, Leu) that confer resistance to dipeptidyl peptidase IV cleavage and other proteolytic-degradation pathways. The base GHRH(1-29) sequence is the minimum sequence required for full agonist activity at the GHRH receptor. The substitutions give the compound the “modified GRF 1-29” descriptive name; the parallel “CJC-1295 No DAC” name describes its relationship to the DAC variant in the Conjuchem development program.
Both names refer to the same molecule. The Jetté CJC-1295 identification paper characterised the original DAC variant as a long-acting GRF receptor agonist (PMID 15817669); the No DAC variant uses the same protease-resistant backbone without the albumin-binding modification. The pharmacology consequences of the DAC vs No DAC distinction were elaborated in the Teichman clinical-pharmacology work (PMID 16352683) and the Ionescu pulsatile-GH-secretion work (PMID 17018654).
Research-supply contexts more commonly use “CJC-1295 No DAC” as the catalog-listing name; the Mod GRF 1-29 name appears in older research literature and in some specialty supply catalogs.
Why this matters in research context
The naming overlap can confuse researchers searching the literature — Mod GRF 1-29 and CJC-1295 No DAC are the same compound under different names. The Ronin catalog uses CJC-1295 No DAC as the canonical name; researchers encountering Mod GRF 1-29 in published protocols can substitute the catalog compound directly.
Related compounds
- CJC-1295 No DAC 10mg — the catalog compound corresponding to Mod GRF 1-29
- CJC-1295 + Ipamorelin Blend — combined-formulation
Related research questions
- What is CJC-1295 No DAC used for?
- What is the half-life of CJC-1295 No DAC?
- What is the difference between CJC-1295 with and without DAC?
References
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-4797. [PMID 17018654]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. CJC-1295 No DAC is sold strictly as a research-grade reagent for laboratory and bench research applications.